Biogen resurrects aducanumab, arguing expanded data set supports FDA filing in Alzheimer's

Biogen is planning to file for FDA approval of its failed Alzheimer’s disease drug aducanumab. The drug flunked a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.